Combining Immediate-Release and Extended-Release Oxycodone for Chronic Pain Management

General Principles

The American Medical Association recommends avoiding the use of immediate-release opioids in combination with extended-release/long-acting (ER/LA) opioids, given potentially increased risk and diminishing returns of such an approach for chronic pain, except in specific clinical circumstances, and requires careful justification and monitoring 1, 2, 3
The Centers for Disease Control and Prevention (CDC) guidelines acknowledge specific situations where combining these formulations may be necessary, such as transitioning patients from ER/LA opioids to immediate-release opioids, temporary postoperative use, and breakthrough pain management in cancer patients 2, 4

The National Comprehensive Cancer Network (NCCN) recommends combining immediate-release and extended-release opioids for transitioning patients from ER/LA opioids to immediate-release opioids by temporarily using lower dosages of both, for temporary postoperative use of short-term opioids in a patient already receiving ER/LA opioids, and for breakthrough pain management in cancer patients on stable around-the-clock opioid therapy 2, 4

The NCCN recommends adding extended-release formulation to provide background analgesia for control of chronic persistent pain once controlled on stable doses of short-acting opioids, providing rescue doses of short-acting opioids for breakthrough pain at 10%-20% of 24-hour oral dose, and using the same opioid for both short-acting and extended-release forms when possible 4

The CDC recommends calculating total daily opioid dose based on previous 24-hour consumption, prescribing ER/LA for baseline pain, limiting immediate-release to breakthrough pain, and monitoring for persistent need 4
The American College of Physicians recommends avoiding increasing dosage to ≥90 MME/day or carefully justifying a decision to titrate dosage to ≥90 MME/day, and implementing additional precautions including increased frequency of follow-up and consideration of offering naloxone 1, 2, 3

The CDC recommends ensuring the patient is opioid-tolerant, calculating total daily opioid dose, prescribing ER/LA for baseline pain, limiting immediate-release to breakthrough pain, and monitoring for persistent need 3, 4

The NCCN recommends a safer alternative approach, including OxyContin ER 20-30 mg every 12 hours for baseline pain control, and immediate-release oxycodone 5-10 mg every 2 hours as needed for breakthrough pain, to maintain total daily dose while reducing scheduled opioid exposure and overdose risk 4, 6